These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

560 related items for PubMed ID: 12384841

  • 1. Antifungal resistance in pathogenic fungi.
    Perea S, Patterson TF.
    Clin Infect Dis; 2002 Nov 01; 35(9):1073-80. PubMed ID: 12384841
    [Abstract] [Full Text] [Related]

  • 2. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.
    Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE.
    Clin Infect Dis; 2000 Apr 01; 30(4):662-78. PubMed ID: 10770728
    [Abstract] [Full Text] [Related]

  • 3. Antifungal drug resistance: limited data, dramatic impact?
    Rogers TR.
    Int J Antimicrob Agents; 2006 Jun 01; 27 Suppl 1():7-11. PubMed ID: 16701982
    [Abstract] [Full Text] [Related]

  • 4. Pharmacodynamic implications for use of antifungal agents.
    Lewis RE.
    Curr Opin Pharmacol; 2007 Oct 01; 7(5):491-7. PubMed ID: 17616480
    [Abstract] [Full Text] [Related]

  • 5. Update on clinical antifungal susceptibility testing for Candida species.
    Lewis RE, Klepser ME, Pfaller MA.
    Pharmacotherapy; 1998 Oct 01; 18(3):509-15. PubMed ID: 9620102
    [Abstract] [Full Text] [Related]

  • 6. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C, Castagnola E.
    Recenti Prog Med; 1999 Oct 01; 90(10):545-57. PubMed ID: 10592741
    [Abstract] [Full Text] [Related]

  • 7. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, Han XY, Rolston KV, Safdar A, Raad II, Kontoyiannis DP.
    Medicine (Baltimore); 2003 Sep 01; 82(5):309-21. PubMed ID: 14530780
    [Abstract] [Full Text] [Related]

  • 8. [Drug resistance in the treatment of invasive fungal infections].
    Nordøy I, Gaustad P.
    Tidsskr Nor Laegeforen; 2008 Nov 20; 128(22):2607-11. PubMed ID: 19023376
    [Abstract] [Full Text] [Related]

  • 9. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
    Pinto PM, Weikert-Oliveira Rde C, Lyon JP, Cury VF, Arantes RR, Koga-Ito CY, Resende MA.
    Microbiol Res; 2008 Nov 20; 163(5):579-85. PubMed ID: 16962755
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological advances in the treatment of invasive candidiasis.
    Deck DH, Guglielmo BJ.
    Expert Rev Anti Infect Ther; 2006 Feb 20; 4(1):137-49. PubMed ID: 16441215
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Fungal infections: involved species and minimal inhibitory concentrations of common antifungal agents].
    Dei-Cas E, Fruit J, Poulain D, Dutoit E, Chendid H, Vernes A.
    Ann Biol Clin (Paris); 1984 Feb 20; 42(6):415-8. PubMed ID: 6543419
    [Abstract] [Full Text] [Related]

  • 15. Antifungal treatment in pediatric patients.
    Zaoutis TE, Benjamin DK, Steinbach WJ.
    Drug Resist Updat; 2005 Aug 20; 8(4):235-45. PubMed ID: 16054422
    [Abstract] [Full Text] [Related]

  • 16. Susceptibility of candida isolates from denture-related stomatitis to antifungal agents in vitro.
    Dorocka-Bobkowska B, Konopka K.
    Int J Prosthodont; 2007 Aug 20; 20(5):504-6. PubMed ID: 17944341
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of amphotericin B and flucytosine against fluconazole-resistant Candida inconspicua clinical isolates.
    Majoros L, Kardos G, Feiszt P, Szabó B.
    J Antimicrob Chemother; 2005 Jul 20; 56(1):253-4. PubMed ID: 15911550
    [No Abstract] [Full Text] [Related]

  • 18. Candida glabrata infection after total hip arthroplasty.
    Ramamohan N, Zeineh N, Grigoris P, Butcher I.
    J Infect; 2001 Jan 20; 42(1):74-6. PubMed ID: 11243760
    [Abstract] [Full Text] [Related]

  • 19. Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital.
    Muñoz P, Sánchez-Somolinos M, Alcalá L, Rodríguez-Créixems M, Peláez T, Bouza E.
    J Antimicrob Chemother; 2005 Feb 20; 55(2):188-93. PubMed ID: 15650001
    [Abstract] [Full Text] [Related]

  • 20. Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.
    Te Dorsthorst DT, Mouton JW, van den Beukel CJ, van der Lee HA, Meis JF, Verweij PE.
    Antimicrob Agents Chemother; 2004 Aug 20; 48(8):3147-50. PubMed ID: 15273136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.